FDA grants breakthrough designation to IPF investigational therapy

The FDA has granted breakthrough designation to a novel investigational therapy, BI 1015550, for treatment of patients with idiopathic pulmonary fibrosis, according to a press release from Boehringer Ingelheim.
“The accelerated development of BI 1015550 is part of Boehringer Ingelheim’s next wave of potential innovative treatments for interstitial lung diseases aimed at preserving lung function and improving the lives of patients,” Thomas Sec, MD, senior vice president of medicine and regulatory affairs at Boehringer Ingelheim, said in the release.
BI 1015550 is an

The FDA has granted breakthrough designation to a novel investigational therapy, BI 1015550, for treatment of patients with idiopathic pulmonary fibrosis, according to a press release from Boehringer Ingelheim.
“The accelerated development of BI 1015550 is part of Boehringer Ingelheim’s next wave of potential innovative treatments for interstitial lung diseases aimed at preserving lung function and improving the lives of patients,” Thomas Sec, MD, senior vice president of medicine and regulatory affairs at Boehringer Ingelheim, said in the release.
BI 1015550 is an